ĐÁNH GIÁ KẾT QUẢ HOÁ TRỊ TÂN HỖ TRỢ UNG THƯ BIỂU MÔ BUỒNG TRỨNG GIAI ĐOẠN III-IV BẰNG PHÁC ĐỒ PACLITAXEL – CARBOPLATIN 3 CHU KỲ TẠI BỆNH VIỆN UNG BƯỚU THÀNH PHỐ CẦN THƠ NĂM 2024-2025

Abstract

Background: Ovarian cancer is one of the most common female genital tract cancers and poor prognosis because of difficult diagnosis, as most cases are detected at stages III and IV. To achieve optimal surgery, neoadjuvant chemotherapy with the Paclitaxel-Carboplatin regimen is required, followed by reevaluation after three cycles in patients with stage III-IV cancer who are not eligible for immediate surgery. Objectives: To describe the clinical and subclinical characteristics and evaluate the outcomes of chemotherapy, as well as the factors related to the response to three cycles of neoadjuvant Paclitaxel-Carboplatin chemotherapy in patients with stage III-IV epithelial ovarian cancer. Materials and methods: A prospective, uncontrolled clinical intervention study was conducted on 31 patients at Can Tho Oncology Hospital. Results: The most common symptom was abdominal pain (96.8%), serous carcinoma being the most frequent type (48.4%), and stage IV was more predominant (54.8%). Partial response was dominant (77.4%), complete response (6.5%). Side effects included leukopenia (38.7%), anemia (32.1%), thrombocytopenia (22.6%), nausea-vomiting (21.6%), diarrhea (22.6%), hair loss (100%), and limb numbness (67.7%). Neoadjuvant chemotherapy response rate is related to: stage, pleural effusion. Conclusion: The three-cycle neoadjuvant Paclitaxel-Carboplatin regimen is effective in reducing tumor size, rate of response 83,9%, facilitating the surgical process and relatively safe.